IceCure Medical (ICCM) awards COO 141K new RSUs

Rhea-AI Filing Summary

Levav Shay reported acquisition or exercise transactions in this Form 4 filing.

IceCure Medical Ltd. (ICCM) reported that Chief Operating Officer Levav Shay received a grant of 141,483 restricted share units (RSUs) on August 14, 2026, at a stated price of $0.00 per share. Twenty-five percent of this award vests on August 11, 2027, with the remaining 75% vesting in twelve equal quarterly installments of 6.25%. After this grant, Shay holds 146,303 RSUs in total, including earlier RSU awards from 2024–2026, most of which remain unvested as of August 13, 2026.

Insider Trade Summary

Net Buyer: 141,483 shares

Net Buy 1 txn

Insider Levav Shay

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares F1	141,483	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 146,303 shares (Direct)

Footnotes (1)

1. F1. Represents (i) 141,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 2,727 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iii) 1,447 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (iv) 646 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (iv) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

Key Figures

New RSU grant: 141,483 RSUs Grant price per share: $0.00 Total RSUs after transaction: 146,303 RSUs +4 more

7 metrics

New RSU grant 141,483 RSUs Restricted share units granted to COO Levav Shay on August 14, 2026

Grant price per share $0.00 Stated price per RSU for the August 14, 2026 grant

Total RSUs after transaction 146,303 RSUs Total RSU holdings for Levav Shay following the reported grant

Initial vesting tranche 25% Portion of each RSU award that vests on the specified first vesting date

Quarterly vesting installments 6.25% Percentage of RSUs vesting in each quarterly installment after the initial 25%

Prior RSU grant (July 2, 2024) 2,727 RSUs RSUs granted July 2, 2024; 25% vested July 29, 2026

Reverse share split ratio 1-for-30 RSU holdings in certain grants adjusted to reflect the issuer's reverse share split

Key Terms

restricted share units, vesting, reverse share split

3 terms

restricted share units financial

"Represents (i) 141,483 restricted share units ("RSUs") granted on August 14, 2026"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

vesting financial

"25% of which vest on August 11, 2027, and the remaining 75% vest"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

reverse share split financial

"have been adjusted to reflect the Issuer's 1-for-30 reverse share split"

A reverse share split is when a company reduces the number of its shares outstanding by combining multiple shares into one, effectively increasing the price of each share. For investors, this can help improve the company's image or meet stock exchange listing requirements, but it does not change the total value of their investment. It’s similar to turning many small pieces of a puzzle into fewer larger pieces—nothing new is added or lost, just rearranged.

FAQ

What did IceCure Medical (ICCM) disclose about Levav Shay in this Form 4?

IceCure Medical disclosed that COO Levav Shay received a grant of 141,483 RSUs on August 14, 2026. This equity award is part of his compensation and follows a multi-year vesting schedule extending beyond 2027.

How many RSUs were granted to IceCure Medical (ICCM) COO Levav Shay and at what price?

COO Levav Shay was granted 141,483 restricted share units at a stated price of $0.00 per share. These RSUs represent equity-based compensation that will vest over time rather than an open-market purchase of shares.

What is the vesting schedule for the new RSU grant to IceCure Medical (ICCM) COO Levav Shay?

For the 141,483 new RSUs, 25% vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25%. This structure spreads vesting over several years, aligning compensation with continued service.

What are Levav Shay’s total RSU holdings reported by IceCure Medical (ICCM) after this transaction?

After the reported grant, Levav Shay holds 146,303 RSUs in total. This figure includes the new 141,483 RSUs and prior RSU awards granted in 2024–2026, adjusted for IceCure Medical’s 1-for-30 reverse share split.

How do earlier RSU awards to IceCure Medical (ICCM) COO Levav Shay vest?

Earlier RSU awards of 2,727, 1,447, and 646 RSUs each vest 25% on specified dates in 2026–2027, with the remaining 75% vesting in equal quarterly installments of 6.25%. Most of these RSUs remained unvested as of August 13, 2026.

What reverse share split did IceCure Medical (ICCM) apply to Levav Shay’s RSU holdings?

IceCure Medical applied a 1-for-30 reverse share split to relevant RSU holdings. The filing notes that RSU awards described in certain clauses were adjusted to reflect this reverse split when reporting Levav Shay’s current RSU amounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/17/2026 - 08:17 AM Accepted by SEC EDGAR 08/17/2026 - 08:16 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Levav Shay

(Last) (First) (Middle)

7 HA'ESHEL ST., PO BOX 3163

(Street)

CAESAREA 3079504

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
IceCure Medical Ltd. [ ICCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/14/2026		A		141,483	A	$0	146,303(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents (i) 141,483 restricted share units ("RSUs") granted on August 14, 2026, 25% of which vest on August 11, 2027, and the remaining 75% vest in twelve equal quarterly installments of 6.25% thereafter, (ii) 2,727 RSUs granted on July 2, 2024, 25% of which vested on July 29, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, (iii) 1,447 RSUs granted on November 5, 2025, 25% of which vest on November 5, 2026, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter, and (iv) 646 RSUs granted on March 16, 2026, 25% of which vest on March 16, 2027, and the remaining 75% vest in equal quarterly installments of 6.25% thereafter. Except for the 25% tranche of the RSUs granted on July 2, 2024 that vested on July 29, 2026, all of the foregoing RSUs remain unvested as of August 13, 2026. The holdings described in clauses (ii) through (iv) have been adjusted to reflect the Issuer's 1-for-30 reverse share split.

	/s/ Shay Levav	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)